Loading company…
Valderm ApS is developing valrubicin, a second-generation anthracycline, as a once-daily topical treatment for skin diseases.
Valderm ApS is based in Denmark and is developing valrubicin, a second-generation anthracycline, for once-daily topical treatment of hyperproliferative skin diseases such as psoriasis. Its listed stage is Series A.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in